Tempus AI Announces Clinical Availability of xH Sequencing Test with High Accuracy Metrics
Tempus AI announced the clinical availability of its advanced sequencing test, xH, which detects oncologic targets using whole-genome sequencing. The company reported high statistical accuracy metrics for various genomic alterations and emphasized the potential impact on hematologic oncology care.
Tickers: $TEM
Topics: AI stocks genomic sequencing healthcare technology short interest